The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The Liver X Receptor Ligand T0901317 Decreases Amyloid β Production in Vitro and in a Mouse Model of Alzheimer's Disease
Open accessAbstract
Recent studies indicate that oxysterols, which are ligands for the nuclear hormone liver X receptors (LXR), decrease amyloid beta (Abeta) secretion in vitro. The effect was attributed primarily to the ATP-binding cassette transporter A1 (ABCA1) transcriptionally up-regulated by ligand-activated LXRs. We now examined the effect of the synthetic LXR ligand T0901317, which can be used in vivo, on Abeta production in vitro and in APP23 transgenic mice. T0901317 applied to a variety of in vitro models, including immortalized fibroblasts from Tangier patients, and primary embryonic mouse neurons caused a concentration-dependent decrease in Abeta secretion, and this effect was increased by the addition of apolipoprotein A-I. The inhibition of Abeta production by T0901317 was cell-type specific, being more prominent in primary neurons than in non-neuronal cells. Tangier fibroblasts lacking a functional ABCA1 secreted more Abeta than control fibroblasts, thus demonstrating the role of ABCA1 in amyloid precursor protein (APP) processing and Abeta generation. T0901317 treatment of 11-week-old APP23 mice for 6 days showed a significant increase in ABCA1 expression and a decrease in the ratio of soluble APP (sAPP)beta- to sAPPalpha-cleavage products. Most importantly, the treatment caused a statistically significant reduction in the levels of soluble Abeta40 and of Abeta42 in the brain these mice. Our experiments demonstrate that T0901317 decreases amyloidogenic processing of APP in vitro and in vivo, thus supporting the search for potent and specific LXR ligands with properties allowing therapeutic application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“dosing of APP transgenic mice with LXR agonists, which increase murine CNS apoE levels, also decrease A levels (Koldamova et al., 2005;Burns et al., 2006;Riddell et al., 2007).”
From Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels (2008) · cites this paper as Koldamova et al., 2005
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LXR agonist treatment alleviates AD-like pathology in mouse models of amyloidosis, possibly by inducing Abca1 expression (29, 43–48).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Koldamova et al. and Sun et al. reported that ABCA1 induction decreases Aβ levels in cells by inhibiting both β- and γ-cleavage of APP [62-64].”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ABCA1 gene ablation in mice decreased APOE lipidation and levels and increased Aβ accumulation in APP transgenic mouse models.”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LXR agonists have been shown to decrease A deposition in the brain while modestly increasing apoE expression (Koldamova et al., 2005;Zelcer et al., 2007;Fitz et al., 2010).”
From Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis (2014) · cites this paper as Koldamova et al., 2005
Experimental — accuracy not yet measured
In the citing paper
“Interestingly, several genes expressed in the liver including liver X receptors (LXRs) have been suggested as potential therapeutic targets for AD [189–191].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
Bodzioch, M., Orsó, E., Klucken, J., Langmann, T., Böttcher, A., Diederich, W., Drobnik, W., Barlage, S., Büchler, C., Porsch-Özcürümez, M., et al. (1999) · Nature Genetics · doi:10.1038/11914 · Cited by 1,512
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Self-citationRole of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Piette, J.-C., Deleuze, J.-F., Brewer, H. B., Duverger, N., Denèfle, P., et al. (1999) · Nature Genetics · doi:10.1038/11921 · Cited by 1,433
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J. A., Medina, J. C., Li, L., Lustig, K. D., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,303
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0304 · Cited by 783
Cited by
Sorted by citations
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Integration of metabolism and inflammation by lipid-activated nuclear receptors
Bensinger, S. J., & Tontonoz, P. (2008) · Nature · doi:10.1038/nature07202 · Cited by 827
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782
LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism
Kalaany, N. Y., & Mangelsdorf, D. J. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.033104.152158 · Cited by 623
Klunk, W. E., Lopresti, B. J., Ikonomović, M. D., Lefterov, I. M., Koldamova, R. P., Abrahamson, E. E., Debnath, M. L., Holt, D. P., Huang, G.-F., Shao, L., et al. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2990-05.2005 · Cited by 376
Self-citationAttenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors
Zelcer, N., Khanlou, N., Clare, R., Jiang, Q., Reed-Geaghan, E. G., Landreth, G. E., Vinters, H. V., & Tontonoz, P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701096104 · Cited by 358
Mandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355
Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice
Koldamova, R., Staufenbiel, M., & Lefterov, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504513200 · Cited by 350
Self-citationImpact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
Riddell, D. R., Zhou, H., Atchison, K., Warwick, H. K., Atkinson, P. J., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1972-08.2008 · Cited by 346
Deletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508780200 · Cited by 325
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 283
Xiong, H., Callaghan, D., Jones, A., Walker, D. G., Lue, L., Beach, T. G., Sue, L. I., Woulfe, J., Xu, H., Stanimirovic, D. B., et al. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.10.005 · Cited by 293
Abildayeva, K., Jansen, P. J., Hirsch-Reinshagen, V., Bloks, V. W., Bakker, A. H. F., Ramaekers, F. C. S., de Vente, J., Groen, A. K., Wellington, Kuipers, F., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601019200 · Cited by 267
Riddell, D. R., Zhou, H., Comery, T. A., Kouranova, E., Lo, C. F., Warwick, H. K., Ring, R. H., Kirksey, Y., Aschmies, S., Xu, J., et al. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.01.011 · Cited by 244
Role of ATP‐binding cassette transporters in brain lipid transport and neurological disease
Kim, W. S., Weickert, C. S., & Garner, B. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05099.x · Cited by 252
Evidence for impaired amyloid β clearance in Alzheimer's disease
Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., & Landreth, G. E. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt187 · Cited by 249
Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J.-F., Naus, K. E., McIsaac, S. A., Parkinson, P. F., Chan, J. Y., Tansley, G. H., Hayden, M. R., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508781200 · Cited by 233
Up‐regulation of the α‐secretase ADAM10 by retinoic acid receptors and acitretin
Tippmann, F., Hundt, J., Schneider, A., Endres, K., & Fahrenholz, F. (2009) · The FASEB Journal · doi:10.1096/fj.08-121392 · Cited by 231
Katz, A., Udata, C., Ott, E., Hickey, L., Burczynski, M. E., Burghart, P. H., Vesterqvist, O., & Xu, M. J. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009335768 · Cited by 229
Uddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1237-z · Cited by 212
Donkin, J. J., Stukas, S., Hirsch-Reinshagen, V., Namjoshi, D., Wilkinson, A., May, S., Chan, J., Fan, J., Collins, J., & Wellington, C. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.108100 · Cited by 200
Apolipoproteins in the brain: implications for neurological and psychiatric disorders
Elliott, D. A., Weickert, C. S., & Garner, B. (2010) · Clinical Lipidology · doi:10.2217/clp.10.37 · Cited by 194
Kim, W. S., Rahmanto, A. S., Kamili, A., Rye, K.-A., Guillemin, G. J., Gelissen, I. C., Jessup, W., Hill, A. F., & Garner, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607831200 · Cited by 191
Terwel, D., Steffensen, K. R., Verghese, P. B., Kummer, M. P., Gustafsson, J.-Å., Holtzman, D. M., & Heneka, M. T. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6546-10.2011 · Cited by 190
ApoE Lipidation as a therapeutic target in Alzheimer’s disease
Lanfranco, M. F., Ng, C. A., & Rebeck, G. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176336 · Cited by 189
The Role of APOE and TREM2 in Alzheimer′s Disease—Current Understanding and Perspectives
Wolfe, C. M., Fitz, N. F., Nam, K. N., Lefterov, I. M., & Koldamova, R. P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010081 · Cited by 201
Self-citationAlzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function
Battista, A. M. D., Heinsinger, N. M., & Rebeck, G. W. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160401115127 · Cited by 189
Oxysterols, cholesterol homeostasis, and Alzheimer disease
Vaya, J., & Schipper, H. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04689.x · Cited by 188
HDL and cognition in neurodegenerative disorders
Hottman, D. A., Chernick, D., Cheng, S., Wang, Z., & Li, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.015 · Cited by 188
Formation and function of apolipoprotein E-containing lipoproteins in the nervous system
Vance, J. E., & Hayashi, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.007 · Cited by 155
Lee, C. Y. D., Tse, W., Smith, J. D., & Landreth, G. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.295451 · Cited by 178
Fitz, N. F., Cronican, A., Pham, T., Fogg, A., Fauq, A. H., Chapman, R., Lefterov, I., & Koldamova, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1051-10.2010 · Cited by 175
Self-citationTargeting liver X receptors in cancer therapeutics
Lin, C., & Gustafsson, J.-Α. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3912 · Cited by 174
Yamazaki, Y., Painter, M. M., Bu, G., & Kanekiyo, T. (2016) · CNS Drugs · doi:10.1007/s40263-016-0361-4 · Cited by 173
The Role of the ATP-Binding Cassette A1 (ABCA1) in Human Disease
Jacobo‐Albavera, L., Domínguez‐Pérez, M., Medina-Leyte, D. J., González-Garrido, A., & Villarreal-Molina, M. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041593 · Cited by 172
Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease
Yao, J., Ho, D. J., Calingasan, N. Y., Pipalia, N. H., Lin, M. T. S., & Beal, M. F. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20121239 · Cited by 162
Kim, W. S., Guillemin, G. J., Glaros, E. N., Lim, C. K., & Garner, B. (2006) · Neuroreport · doi:10.1097/01.wnr.0000221833.41340.cd · Cited by 158
Liver X receptor activation restores memory in aged AD mice without reducing amyloid
Vanmierlo, T., Rutten, K., Dederen, J., Bloks, V. W., van Vark-van der Zee, L. C., Kuipers, F., Kiliaan, A., Blokland, A., Sijbrands, E. J. G., Steinbusch, H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.005 · Cited by 154
Reddy, P. H. (2006) · BioMed Research International · doi:10.1155/jbb/2006/31372 · Cited by 154
Fitz, N. F., Cronican, A. A., Lefterov, I., & Koldamova, R. (2013) · Science · doi:10.1126/science.1235809 · Cited by 151
Self-citationATP-binding cassette transporter A1: From metabolism to neurodegeneration
Koldamova, R., Fitz, N. F., & Lefterov, I. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.007 · Cited by 144
Self-citationHong, C., Duit, S., Jalonen, P., Out, R., Scheer, L., Sorrentino, V., Boyadjian, R., Rodenburg, K. W., Foley, E., Korhonen, L., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.123729 · Cited by 142
Can herbs provide a new generation of drugs for treating Alzheimer’s disease?
Anekonda, T. S., & Reddy, P. H. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.09.001 · Cited by 140
Fitz, N. F., Cronican, A. A., Saleem, M., Fauq, A. H., Chapman, R., Lefterov, I., & Koldamova, R. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1937-12.2012 · Cited by 119
Self-citationInterrelationships Among HDL Metabolism, Aging, and Atherosclerosis
Walter, M. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.181438 · Cited by 137
Self-citationRole of ABC Transporters in the Pathogenesis of Alzheimer’s Disease
Abuznait, A. H., & Kaddoumi, A. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300077c · Cited by 145
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene
Boehm-Cagan, A., & Michaelson, D. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5198-13.2014 · Cited by 134
Chen, S., Wang, J. M., Irwin, R. W., Yao, J., Liu, L., & Brinton, R. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024293 · Cited by 136
Wang, Y., Kumar, N., Crumbley, C., Griffin, P. R., & Burris, T. P. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.012 · Cited by 136
Lefterov, I. M., Fitz, N. F., Cronican, A. A., Fogg, A., Lefterov, P., Kodali, R. B., Wetzel, R. B., & Koldamova, R. P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127738 · Cited by 130
Self-citationLiao, F., Hori, Y., Hudry, E., Bauer, A. Q., Jiang, H., Mahan, T. E., Lefton, K. B., Zhang, T. J., Dearborn, J. T., Kim, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0646-14.2014 · Cited by 128
Genetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126
“Interestingly, several genes expressed in the liver including liver X receptors (LXRs) have been suggested as potential therapeutic targets for AD (Sodhi and Singh, 2013; Zelcer et al., 2007; Koldamova et al., 2005).”
BackgroundNuclear receptors as therapeutic targets for Alzheimer's disease
Mandrekar-Colucci, S., & Landreth, G. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.594043 · Cited by 126
Selective liver X receptor modulators (SLiMs): what use in human health?
Viennois, E., Mouzat, K., Dufour, J., Morel, L., Lobaccaro, J., & Baron, S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.036 · Cited by 132
Coisne, C., Tilloy, S., Monflier, É., Wils, D., Fénart, L., & Gosselet, F. (2016) · Molecules · doi:10.3390/molecules21121748 · Cited by 122
Role of Cholesterol in APP Metabolism and Its Significance in Alzheimer’s Disease Pathogenesis
Maulik, M., Westaway, D. A., Jhamandas, J. H., & Kar, S. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8337-y · Cited by 121
Morales, J. R., Ballesteros, I., Deniz, J. M., Hurtado, O., Vivancos, J., Nombela, F., Lizasoaín, I., Castrillo, A., & Moro, M. Á. (2008) · Circulation · doi:10.1161/circulationaha.108.782300 · Cited by 117
Microglial efferocytosis: Diving into the Alzheimer’s disease gene pool
Romero-Molina, C., Garretti, F., Andrews, S. J., Marcora, E., & Goate, A. M. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.015 · Cited by 111
Fatty acids, lipid metabolism and Alzheimer pathology
Hooijmans, C. R., & Kiliaan, A. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.081 · Cited by 115
Vinuesa, Á., Pomilio, C. J., Gregosa, A., Bentivegna, M., Presa, J., Bellotto, M., Saravia, F., & Beauquis, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653651 · Cited by 117
ABC Transporters and the Alzheimer’s Disease Enigma
Wolf, A. M., Bauer, B., & Hartz, A. M. S. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00054 · Cited by 109
Wada, T., Kang, H. S., Angers, M., Gong, H., Bhatia, S., Khadem, S., Ren, S., Ellis, E. C. S., Strom, S. C., Jetten, A. M., et al. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.040741 · Cited by 103
Impact of Apolipoprotein E on Alzheimer’s Disease
Hauser, P. S., & Ryan, R. O. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990156 · Cited by 103
Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis
Hindinger, C., Hinton, D. R., Kirwin, S. J., Atkinson, R., Burnett, M. E., Bergmann, C. C., & Stohlman, S. A. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21038 · Cited by 103
The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration
Koldamova, R., Fitz, N. F., & Lefterov, I. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.010 · Cited by 102
Self-citationGosselet, F., Candela, P., Sevin, E., Bérézowski, V., Cecchelli, R., & Fénart, L. (2008) · Brain Research · doi:10.1016/j.brainres.2008.10.036 · Cited by 110
ABCA1 influences neuroinflammation and neuronal death
Karasinska, J. M., de Haan, W., Franciosi, S., Ruddle, P., Fan, J., Kruit, J. K., Stukas, S., Lütjohann, D., Gutmann, D. H., Wellington, C. L., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.01.018 · Cited by 104
Nuclear receptors in neurodegenerative diseases
Skerrett, R., Malm, T., & Landreth, G. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.019 · Cited by 94
Lipid metabolism and neuroinflammation in Alzheimer’s disease: a role for liver X receptors
Kang, J., & Rivest, S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1049 · Cited by 94
Hoe, H.-S., Cooper, M. J., Burns, M. P., Lewis, P. A., van der Brug, M., Chakraborty, G., Cartagena, C. M., Pak, D. T. S., Cookson, M. R., & Rebeck, G. W. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3135-07.2007 · Cited by 90
The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease
Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91
Lee, L., Sakurai, M., Matsuzaki, S., Arancio, O., & Fraser, P. E. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8257-7 · Cited by 94
Modulation of liver X receptor signaling as novel therapy for prostate cancer
Chuu, C., Kokontis, J. M., Hiipakka, R. A., & Liao, S. (2007) · Journal of Biomedical Science · doi:10.1007/s11373-007-9160-8 · Cited by 95
Lefterov, I., Bookout, A., Wang, Z., Staufenbiel, M., Mangelsdorf, D., & Koldamova, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-20 · Cited by 89
Self-citationSkerrett, R., Pellegrino, M. P., Casali, B. T., Taraboanta, L., & Landreth, G. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.652008 · Cited by 91
Extra-virgin olive oil for potential prevention of Alzheimer disease
Román, G. C., Jackson, R. E., Reis, J. J., Roman, A., Toledo, J. B., & Toledo, E. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.07.017 · Cited by 95
Brain injury-induced dysfunction of the blood brain barrier as a risk for dementia
Abrahamson, E. E., & Ikonomović, M. D. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113257 · Cited by 91
The effects of ABCA1 on cholesterol efflux and Aβ levels in vitro and in vivo
Burns, M. P., Vardanian, L., Pajoohesh‐Ganji, A., Wang, L., Cooper, M., Harris, D. C., Duff, K., & Rebeck, G. W. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03925.x · Cited by 106
Apolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities
Belaidi, A. A., Bush, A. I., & Ayton, S. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00843-y · Cited by 91
Why lipids are important for Alzheimer disease?
Hirsch-Reinshagen, V., Burgess, B. L., & Wellington, C. L. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0012-2 · Cited by 86
Targeting liver X receptors in human health: deadlock or promising trail?
Viennois, É., Pommier, A., Mouzat, K., Oumeddour, A., Hajjaji, F.-Z. E., Dufour, J., Caira, F., Volle, D. H., Baron, S., & Lobaccaro, J. A. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.547853 · Cited by 98
LXR Agonists: New Potential Therapeutic Drug for Neurodegenerative Diseases
Xu, P., Li, D., Tang, X., Bao, X., Huang, J., Tang, Y., Yang, Y., Xu, H., & Fan, X. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8461-3 · Cited by 84
ABC transporters: human disease and pharmacotherapeutic potential
Moore, J. M., Bell, E. L., Hughes, R. O., & Garfield, A. S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.11.001 · Cited by 94
Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases?
Mouzat, K., Chudinova, A., Polge, A. S., Kantar, J., Camu, W., Raoul, C., & Lumbroso, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163858 · Cited by 86
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Proteomic Identification of Lower Apolipoprotein A-I in Alzheimer’s Disease
Liu, H., Hu, C., Chang, J., Sung, S., Lee, L.-S., Yuan, R.-Y., & Leu, S. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000090676 · Cited by 75
Behl, T., Kaur, I., Sehgal, A., Kumar, A., Uddin, M. S., & BUNGAU, S. G. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02211-x · Cited by 78
Therapeutic potential of nuclear receptor agonists in Alzheimer's disease
Moutinho, M., & Landreth, G. E. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075556 · Cited by 76
Zhao, J., Fu, Y., Liu, C.-C., Shinohara, M., Nielsen, H. M., Dong, Q., Kanekiyo, T., & Bu, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.526095 · Cited by 67
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72
The liver X receptor: Control of cellular lipid homeostasis and beyond
Oosterveer, M. H., Grefhorst, A., Groen, A. K., & Kuipers, F. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.03.002 · Cited by 72
Wu, C., Chen, C.-C., Lai, C.-Y., Hung, T., Lin, C.-C., Chao, M., & Chen, S. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0524-8 · Cited by 72
Brain cholesterol metabolism and neurologic disease
Benarroch, E. E. (2008) · Neurology · doi:10.1212/01.wnl.0000333215.93440.36 · Cited by 68
Saint-Pol, J., Vandenhaute, E., Boucau, M.-C., Candela, P., Dehouck, L., Cecchelli, R., Dehouck, M.-P., Fenart, L., & Gosselet, F. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-112090 · Cited by 64
Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation
Willems, S., Zaienne, D., & Merk, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00186 · Cited by 66
Liver X Receptor: an oxysterol sensor and a major player in the control of lipogenesis
Ducheix, S., Lobaccaro, J. A., Martin, P. G. P., & Guillou, H. (2011) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2011.06.004 · Cited by 71
Burgess, B. L., Parkinson, P. F., Racke, M. M., Hirsch‐Reinshagen, V., Fan, J., Wong, C. A., Stukas, S. K., Théroux, L., Chan, J. Y., Donkin, J. J., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700481-jlr200 · Cited by 66
Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity
Mounier, A., Georgiev, D., Nam, K. N., Fitz, N. F., Castranio, E. L., Wolfe, C. M., Cronican, A. A., Schug, J., Lefterov, I., & Koldamova, R. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1001-15.2015 · Cited by 64
Self-citation
Metadata
- Authors
- Koldamova, R. P., Lefterov, I. M., Staufenbiel, M., Wolfe, D., Huang, S., Glorioso, J. C., Walter, M., Roth, M. G., & Lazo, J. S.
- Affiliations
- University of Pittsburgh (US)
- Novartis Institutes for BioMedical Research (CH)
- University of Münster (DE)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Koldamova, Radosveta P.
- Lefterov, Iliya M.
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 280
- Issue
- 6
- Pages
- 4079-4088
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1996457468
- Cited by
- 279
- References
- 55
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 11 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 11 · 2016: 13 · 2015: 15 · 2014: 17 · 2013: 22 · 2012: 15
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Pittsburgh
- National Institutes of Health
- National Institute on Aging (AG 18558, AG 23304, R03AG023304)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- liver X receptor, T0901317, amyloid-beta, Alzheimer's disease, ABCA1, oxysterols, APP processing, APP23 transgenic mice, apolipoprotein A-I, soluble APP alpha, cell type specificity, LXR ligands
- MeSH terms
- Liver X Receptors, Benzenesulfonamides, Alzheimer Disease, Animals, Anticholesteremic Agents, Brain, Cloning, Molecular, Disease Models, Animal, DNA-Binding Proteins, Enzyme-Linked Immunosorbent Assay, Fibroblasts, Fluorocarbons, Humans, Hydrocarbons, Fluorinated, Ligands, Mice, Inbred C57BL, Mice, Transgenic, Neurons, Protein Binding, Sulfonamides, Time Factors, Transcription, Genetic, Transfection, Blotting, Western, Up-Regulation, Amyloid beta-Protein Precursor, Apolipoprotein A-I, DNA, Complementary, Simplexvirus, Receptors, Cytoplasmic and Nuclear, Immunoprecipitation, Mice, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
